Onconetix (ONCO) EBIT (2021 - 2026)

Onconetix (ONCO) has reported EBIT for 6 consecutive years, with -$2.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBIT fell 41.1% year-over-year to -$2.7 million in Q2 2026; TTM through Jun 2026 was -$16.3 million, a 64.78% increase from a year earlier, with the FY2025 full-year figure at -$17.9 million, up 68.39% from the prior year.
• EBIT was -$2.7 million for Q2 2026 at Onconetix, up from -$10.2 million in the prior quarter.
• Over five years, EBIT peaked at -$1.3 million in Q4 2025 and troughed at -$29.1 million in Q4 2024.
• A 5-year average of -$7.6 million and a median of -$4.1 million in 2022 frame the typical range for EBIT.
• Across the five-year window, EBIT tumbled 579.26% in 2023 and jumped 95.6% in 2025, its largest moves.
• Over 5 years, EBIT stood at -$3.2 million in 2022, then plunged by 579.26% to -$22.0 million in 2023, then tumbled by 32.19% to -$29.1 million in 2024, then jumped by 95.6% to -$1.3 million in 2025, then sank by 113.12% to -$2.7 million in 2026.
• The last three EBIT figures came in at -$2.7 million (Q2 2026), -$10.2 million (Q1 2026), and -$1.3 million (Q4 2025), per Business Quant data.